Insulin Glargine

  title={Insulin Glargine},
  author={Kate McKeage and Karen L. Goa},
SummaryAbstractInsulin glargine is a recombinant human insulin analogue produced by DNA technology using a nonpathogenic strain of Escherichia coli. Two modifications of human insulin result in a stable molecule which is soluble in slightly acidic conditions (pH 4.0) and precipitates in the neutral pH of subcutaneous tissue. Because of these properties, absorption of insulin glargine is delayed and the analogue provides a fairly constant, basal insulin supply without peaks in plasma insulin… 

Insulin Glargine

In conclusion, insulin glargine is an effective and well tolerated basal insulin therapy when given as a single daily subcutaneous injection to patients with diabetes, with benefits in terms of glycaemic control and reduced frequency of hypoglycaemia over regimens based on conventional basal insulins.

Long-acting hypoglycemic effects of PEGylated FGF21 and insulin glargine in mice with type 1 diabetes.

  • P. XuX. Ye Deshan Li
  • Biology, Medicine
    Journal of diabetes and its complications
  • 2015

Basalog® is similar to Lantus® in producing glycemic control in patients with type 1 diabetes mellitus on multiple daily insulin regimens

Basalog® was found to have similar efficacy and safety as Lantus® in treatment of patients with type 1 diabetes mellitus and there was no statistically significant difference between the groups with respect to change in HbA1c.

Enzyme-Linked Immunosorbent Assay Method Application in the Study of Comparative Pharmacokinetics of Insulin Glargin Preparations

The method adaptation and validation of the ELISA method insulin glargine determination for the pharmacokinetic study, practical approval in the biosimilars clinical trial and the primary endpoint for long-acting insulins – AUCins.0-τ was calculated.

Transgenic Expression and Identification of Recombinant Human Proinsulin in Peanut

Peanut seeds can act as insulin storage sites, which is the foundation for further production of recombinant proinsulin from peanut seeds, and Western blot and GUS staining analysis indicated that some transgenic peanut successfully expressed exogenous proins insulin.

Insulin-induced vascular redox dysregulation in human atherosclerosis is ameliorated by dipeptidyl peptidase 4 inhibition

Results uncover how DPP4 inhibition induces insulin sensitization in the vascular wall and suggest that cotreatment with insulin may be therapeutic for patients with cardiometabolic disease and reveal the detrimental effects of insulin on vascular redox state and endothelial function.

Development and Validation of Approach for the Detection of Neutralizing Antibodies Against Insulin (Glargine) in Human Blood Plasma

The method is based on the use of the iLiteTM Insulin Assay Ready Cells, in the genome of which the firefly luciferase reporter gene is introduced under the control of an insulin-dependent promoter, allowing to determinate neutralizing antibodies to insulin.

Willingness to pay for inhaled insulin

Diabetic patients, particularly those who are not using insulin, indicated that they would prefer inhaled insulin over insulin injection and would be willing to pay a substantial amount per month to use it, and multiple regression analysis showed that income was significantly associated with WTP for inhale insulin.

Discrete, Chiral Polymer-Insulin Conjugates.

A strategy for the synthesis of polymer-protein conjugates based on discrete, chiral polymers synthesized through iterative exponential growth (IEG) is introduced, enabling faster or longer-lasting blood glucose responses in diabetic mice when compared to PEGylated insulin and the commercial insulin variant Lantus.



Insulin Glargine

Four large clinical trials of up to 28 weeks’ duration have shown that a single bedtime dose of insulin glargine, in combination with preprandial short-acting insulin, is as effective or more effective than once or twice daily NPH plus short- acting insulin in improving glycaemic control in patients with type 1 diabetes mellitus.

Insulin glargine: the first clinically useful extended-acting insulin in half a century?

  • P. Home
  • Medicine, Biology
    Expert opinion on investigational drugs
  • 1999
It appears that insulin glargine is a genuinely new addition to the insulin family, and with further clinical experience it may well be possible to achieve better basal blood glucose control (without enhanced risk of hypoglycaemia), particularly at night or in conjunction with rapid-acting insulin analogues.

Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.

Basal insulin glargine administered once daily for 4 weeks as part of a basal-bolus multiple daily insulin regimen was safe and more effective in lowering fasting plasma glucose levels than NPH in patients with type 1 diabetes.

Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes.

Lower FPG levels with fewer episodes of hypoglycemia were achieved with insulin glargine compared with once- or twice-daily NPH insulin as part of a basal-bolus regimen in patients with type 1 diabetes.

Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type 1 diabetes. RhIGF-I in IDDM Study Group.

It is demonstrated that rhIGF/insulin cotherapy improves glycemic control in patients with type 1 diabetes better than optimized insulin management alone; longer-term trials would be required to determine an acceptable benefit-risk profile.

Treatment with human analog (GlyA21, ArgB31, ArgB32) insulin glargine (HOE901) resolves a generalized allergy to human insulin in type 1 diabetes.

The case of a 45-year-old type 1 diabetic Japanese man with generalized allergy to human insulin, who was successfully treated with human analogs and insulin glargine (HOE901), and who was diagnosed with type 1 diabetes because of the high titer of anti-GAD antibody.

Insulin analogs with improved pharmacokinetic profiles.

  • BrangeVølund
  • Medicine, Biology
    Advanced drug delivery reviews
  • 1999

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

Glargine is a peakless insulin, it lasts nearly 24 h, it has lower intersubject variability than NPH and ultralente, and it closely mimics CSII, the gold standard of basal insulin replacement.

Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites.

Subcutaneous absorption of insulin glargine is delayed compared with NPH insulin and there is little or no difference in the absorption rate of insulinglargine between the main subcutaneous injection sites.

Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.

In patients with type 2 diabetes, once-daily bedtime insulin glargine is as effective as once- or twice-daily NPH in improving and maintaining glycemic control and deonstrates a lower risk of nocturnal hypoglycemia and less weight gain compared with NPH insulin.